Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.50 - $21.94
Previous CloseN/A
Volume937.77K
Average Volume (3M)35.69K
Market Cap
$44.32M
Enterprise Value$133.15M
Total Cash (Recent Filing)$23.37M
Total Debt (Recent Filing)$93.13M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Nov 10, 2025EPS Estimate
-4.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding4,043,899
10 Day Avg. Volume28,921
30 Day Avg. Volume35,686
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.00
Enterprise Value/Revenue-1.83
Enterprise Value/Gross Profit-2.30
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$43.00Price Target Upside307.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cash PositionThe sale of FibroGen China to AstraZeneca for approximately $220 million simplifies the company's balance sheet and extends its cash runway into 2028.
Clinical TrialsEncouragement is drawn from initial results generated from the FG-3246 program, which targets CD46, and there is anticipation for continued progress on FG-3246 in mCRPC in the pre-chemotherapy stage.
Regulatory ProgressThe Type C meeting with the FDA clarified details for the upcoming Phase 3 study of roxadustat, which is expected to investigate its safety and efficacy in patients with anemia.
Bears Say
Clinical Trial RisksPotential risks include failed or inconclusive clinical trials, inability to secure adequate funding, and the occurrence of dilutive capital raises.
Competitive MarketGiven the early stage of FG-3246, along with the highly competitive prostate cancer market, it is considered prudent to wait for additional data prior to drawing solid conclusions.
Financial PerformanceFibroGen reported 2Q25 financial results, posting EPS of ($1.88) compared to our estimate of $1.01 and consensus of $1.00.
FibroGen News
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $4.50 and its highest was $21.94 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $44.32M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Nov 10, 2025 which is in 30 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Aug 11, 2025. The company reported -$1.88 earnings per share for the quarter, beating the consensus estimate of -$2.303 by $0.423.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -4.01.
How many shares outstanding does FibroGen have?
FibroGen has 4,043,899 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$1.88 in its last earnings report, beating expectations of -$2.303. Following the earnings report the stock price went up 10.514%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (307.58% Upside)
$43.00 (307.58% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 59.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.22%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Company Deck
FGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive outlook, driven by the increased financial consideration from the FibroGen China sale, which extends the company's cash runway significantly. The initiation of new clinical trials and positive regulatory feedback further support this sentiment. However, the limited revenue growth and ongoing net losses were noted as areas of concern.View all FGEN earnings summariesFGEN Stock 12 Month Forecast
Average Price Target
$43.00
▲(307.58% Upside)
Technical Analysis
Ownership Overview
14.61% Insiders
23.85% Mutual Funds
10.54% Other Institutional Investors
47.24% Public Companies and
Individual Investors